[Other] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010)

Closed

bashar@1311 Post time 2024-5-4 19:44:54 | Show all posts |Read mode

Reward30points

Edited by bashar@1311 at 2024-5-6 02:47

journal：Neurology

Authors：Jiwon Oh; Sana Syed; Tong Li; Naji Salloum; Timothy J. Turner; Robert J. Fox

Published date：2023-4-25

DOI：10.1212/wnl.0000000000202287

PDF link：https://syndication.highwire.org ... NL.0000000000202287

Article link：http://dx.doi.org/10.1212/wnl.0000000000202287

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

bashar@1311 Lv.2

Junior Member

post
reply
points
170

[Other] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010) Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010)